CliffBio
small molecule

GABAPENTIN

GABAPENTIN

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameGABAPENTIN
Active ingredientGABAPENTIN
Strength250MG/5ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2013
Marketing statusDISCN

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.